中东_非洲医药行业洞察第三十六版_29页_1mb

Middle East & Africa Pharmaceutical Market Summary

Market Growth

• Total value sales in Q1 2025: $36.82 billion, showing an 11.96% increase year-over-year.
• Volume sales grew by 16.53%, with a compound annual growth rate (CAGR) of 12% over the period discussed.

Key Regional Highlights

• Saudi Arabia led with 19.1% value growth and 38% market share.
• United Arab Emirates recorded 14% value growth.
• North Africa saw varying trends, with Egypt experiencing a 46.9% value increase but overall market stability.

Channel Performance

• Retail channels dominate, accounting for 67.3% of value sales and 81.6% of volume.
• Hospital channels showed growth in specific countries, such as Saudi Arabia (+22.9% PPG value growth).

Company Dynamics

• Multinational companies hold the majority of value share (61.9% in 2025), with Sanofi and Novartis among the top contributors.
• Local/region-specific companies grew at a faster pace (21.96% PPG value increase), particularly in KSA and Algeria.

Therapeutic Areas

• Digestive system and metabolism is the largest therapeutic area (20.4% value share) and fastest growing.
• Anti-infectives and oncology are strong contributors, with high demand in countries like Egypt.

Future Projections

• By 2029, MEA pharmaceutical sales are projected to reach $69.56 billion, with a 1.2% CAGR from 2024-2029 under IQVIA's model.

Data and Enabling Insights

• Comprehensive data coverage across 9 MEA countries, including Algeria, Egypt, Saudi Arabia, and others.
• New tools like Flexview and ESWT provide enhanced tracking for retail and prescription data, driving strategic decisions.